Fibroblast Growth Factor: Will This Hormone Be the Hemoglobin A1c for Managing Phosphorus Balance in Chronic Kidney Disease?

Gutiérrez OM Mannstadt M Isakova T Rauh-Hain JA Tamez H Shah A Smith K Lee H Thadhani R Jüppner H Wolf M . Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008: 359 (6): 584–92.

Komaba H Fukagawa M . FGF23: a key player in mineral and bone disorder in CKD. Nefrología. 2009; 29 (5): 392–6.

Park SY Jeong KH Moon JY Lee SH Ihm CG Rhee SY Woo JT Oh IH Lee TW . The relationship between circulating fibroblast growth factor 23 and bone metabolism factors in Korean hemodialysis patients. Clin Exp Nephrol. 2010. [Epub ahead of print.].

Wolf M . Fibroblast growth factor 23 and the future of phosphorus management. Curr Opin Nephrol Hypertens. 2009; 18 (6): 463–8.

Zisman AL Wolf M . Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease. Curr Opin Nephrol Hypertens. 2010. [Epub ahead of print.].

Peiskerová M Kalousová M Kratochvílová M Dusilová-Sulková S Uhrová J Bandúr S Malbohan IM Zima T Tesar V . Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease? Kidney Blood Press Res. 2009; 32 (4): 276–83. Epub 2009 Oct 1.

Tsagalis G Psimenou E Manios E Laggouranis A . Fibroblast growth factor 23 (FGF23) and the kidney. Int J Artif Organs. 2009; 32: 232–9.

Bergwitz C Jüppner H . Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med. 2010; 61: 91–104.

Kuro-O M . Overview of the FGF23-Klotho axis. Pediatr Nephrol. 2009 Jul 22.

Goebel S Lienau J Rammoser U Seefried L Wintgens KF Seufert J Duda G Jakob F Ebert R . FGF23 is a putative marker for bone healing and regeneration. J Orthop Res. 2009; 27: 1141–6.

Riminucci M Collins MT Fedarko NS Cherman N Corsi A White KE Waguespack S Gupta A Hannon T Econs MJ Bianco P Robey P Gehron . FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003; 112 (5): 683–92.

Wang Y Sun Z . Current understanding of klotho. Ageing Res Rev. 2009; 8 (1): 43–51.

Qunibi WY . Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD). Kidney Int Suppl. 2004;(90): S8–12.

Giachelli CM . The emerging role of phosphate in vascular calcification. Kidney Int. 2009; 75 (9): 890–7.

Oliveira RB Cancela AL Graciolli FG Dos Reis LM Draibe SA Cuppari L Carvalho AB Jorgetti V Canziani ME Moysés RM . Control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2009 Nov 12.

Krishnamurti U Steffes MW . Glycohemoglobin: a primary predictor of the development or reversal of complications of diabetes mellitus. Clin Chem. 2001; 47 (7): 1157–65.

Weykamp C Garry J Mosca A . A review of the challenge in measuring hemoglobin A1c. J Diabetes Sci Technol. 2009; 3 (3): 439–45.

Little R Roberts W . Review of variant hemoglobins interfering with hemoglobin A1c measurement. J Diabetes Sci Technol. 2009; 3 (3): 446–51.

Leslie RD Cohen RM . Biologic variability in plasma glucose, hemoglobin A1c, and advanced glycation end products associated with diabetes complications. J Diabetes Sci Technol. 2009; 3 (4): 635–43.

Higgins T Cembrowski G Tran D Lim E Chan J . Influence of variables on hemoglobin A1c values and nonheterogeneity of hemoglobin A1c reference ranges. J Diabetes Sci Technol. 2009; 3 (4): 644–8.

Nilsson PM Gudbjörnsdottir S Eliasson B Cederholm C ; Steering Committee of the Swedish National Diabetes Register. Smoking is associated with increased HbA1c values and microalbuminuria in patients with diabetes—data from the National Diabetes Register in Sweden. Diabetes Metab. 2004; 30 (3): 261–8.

Higgins T Saw S Sikaris K Cembrowski C Lyon A Khajuria A Tran D . Seasonal variation in hemoglobin A1c: is it the same in both hemispheres? J Diabetes Sci Technol. 2009; 3 (4): 668–71.